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fibrinopeptides [9–11]. However, in contrast to CPR, itMizuho-ku, Nagoya 467-8603
Japan does not play any significant role in dampening fibrinoly-
sis. Moreover, CPN is present in the active form in
plasma, whereas CPR is found in the inactive proCPR
state and is called into play during coagulation [2]. Pre-Summary
viously, the carboxypeptidase activity in plasma respon-
sible for inactivation of bradykinin, anaphylatoxins, andA novel carboxypeptidase R (CPR) inhibitor, related to
other basic carboxy-terminal peptides was consideredpotato carboxypeptidase inhibitor (PCI), was designed
to be due only to CPN [9–11]. However, CPR was alsousing rational structure-based strategies, incorporat-
shown to inactivate bradykinin and anaphylatoxin octa-ing two principle facts: CPR has a strong affinity for
peptides [12, 13]; furthermore, CPR, but not CPN, wasbasic amino acids, and the two lysine and arginine
found to effectively reduce fibrinolysis [14].residues of PCI are orientated in the same direction
As shown in Figure 1, following activation, CPR cataly-and held in close spatial proximity by three disulfide
ses the removal of C-terminal lysine (K) residues frombonds. Initially, a disulfide-bonded fragment of PCI
cell-surface proteins and partially degraded fibrin clots,was synthesized showing weak competitive inhibitory
thereby preventing the binding [15, 16] and activationactivity against CPR. Subsequently, a smaller linear
of plasminogen [5, 14]. Conversion of plasminogen (Glu-9-mer peptide, designated CPI-2KR, was designed/
plasminogen) to its active form, plasmin (Lys-plasminsynthesized and found to be a more efficient competi-
or Lys-plasminogen), requires tissue-plasminogen acti-tive inhibitor of CPR, without affecting the activity of
vator (t-PA), which is an activator of blood clot lysis.the other plasma carboxypeptidase, carboxypepti-
Binding of t-PA to fibrin, via its K binding domain, cataly-dase N. In vitro studies showed that, together with
ses cleavage of Glu-plasminogen (i.e. plasminogen) attissue plasminogen activator, CPI-2KR synergistically
the C terminus of Lys76 to yield Lys-plasminogen (i.e.accelerated fibrinolysis, representing a lead com-
plasmin). Lys-plasminogen has an increased affinity forpound for the design of smaller organic molecules for
fibrin compared to Glu-plasminogen, since the releaseuse in thrombolytic therapy.
of residues 1–76 exposes the kringle 1 domain, which
contains two residues (Arg32 and Arg34), previously
Introduction shown to be responsible for fibrin binding [17]. Studies
have shown that CPR inhibits t-PA-induced lysis only
Carboxypeptidases (CPs) are enzymes that catalyze the when Glu-plasminogen, but not Lys-plasminogen, is
hydrolysis of peptide bonds at the C termini of peptides present, suggesting that its antifibrinolytic effect is pri-
and proteins. Briefly, they have been categorized ac- marily mediated through inhibition of Glu-plasminogen
cording to two principle mechanisms of action: as metal- activation [5]. Therefore, removal of Lys-residues by
locarboxypeptidases (MPs) or cysteine/serine-carboxy- CPR from partially degraded fibrin diminishes the al-
peptidases (Cys/Ser-CP). MPs are distinct from Cys/ ready low binding affinity of Glu-plasminogen to fibrin,
Ser-CPs in that they possess a tightly bound Zn2 atom, essentially prolonging fibrinolysis [3]. Plasmin-mediated
which is directly involved in catalysis, while Cys/Ser- proteolysis of fibrin constitutes a positive-feedback pro-
CPs contain a reactive Cys/Ser residue at the active site cess that enhances plasminogen activation. CPR inhib-
similar to the Ser/His/Asp triad of serine proteases. MPs its fibrinolysis by removing C-terminal lysine residues
can be further subdivided into carboxypeptidase A-like from fibrin, thereby limiting plasmin formation [5, 13, 14].
enzymes, which have a preference for hydrophobic At present, t-PA is the only treatment for thromboem-
bolic stroke approved by the Food and Drug Administra-
tion. However, adverse side effects have recently been4 Correspondence: hiokada@med.nagoya-cu.ac.jp
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Figure 1. Coagulation and Fibrinolysis
Pathway
The action of CPR on fibrinolysis in the pres-
ence/absence of PCI is shown.
reported in some patients, suggesting that t-PA may thrombin, the process is inefficient (Km 0.5–2.1 M; kcat
0.0021 s1), requiring large amounts of thrombin com-modulate N-methyl-D-aspartate (NMDA)-receptor-medi-
ated signaling and excitotoxic neuronal death [18]. To pared to activation by plasmin (Km 55 nM; kcat 0.00044
s1) [22]. In contrast, the complex formed betweenalleviate this problem, the coadministration of potato
carboxypeptidase inhibitor (PCI) with lower doses of thrombin and the endothelial cell receptor, thrombomo-
dulin (TM), can more efficiently activate this zymogent-PA has been suggested, and recent experiments in
animal models have shown that PCI dramatically en- (kcat 0.4–1.2 s1) [22, 23]. Since proCPR is activated by
thrombin, enzymes that regulate the formation of throm-hances clot lysis [19]. PCI [20] is a small 39-residue
protein (MW 4295 Da) that has the ability to selectively bin, such as protein C, are also most likely involved.
Furthermore, the activation of both protein C andinhibit CPR (Figure 1) without affecting the activity of
CPN in the circulation [14]. An understanding of the proCPR is enhanced when thrombin is bound to TM,
which is subsequently liberated into the plasma [22, 24].interaction between CPR and PCI is crucial for the devel-
opment of novel therapeutics for use in thrombolytic Recent studies have showed that although higher TM
concentrations (10 and 25 nM) upregulated fibrinolysis,therapy. Our studies have lead to the design of a smaller
peptide inhibitor of CPR, designated CPI-2KR, which attributed to the activation of protein C, lower TM con-
centrations (5 nM) resulted in downregulation of fibri-shows similar biological activity to PCI in vitro and is a
competitive inhibitor of CPR. While this peptide may be nolysis due to proCPR activation [25].
Recently, proCPR has been shown to be an acuteuseful for the treatment and/or prevention of thrombo-
sis, it also represents a starting point for the design phase protein, with upregulation of its mRNA in re-
sponse to inflammation [26, 27]. On the other hand, inof low molecular weight organic molecules, which are
preferable and more useful alternatives. In this report, diseases where circulating TM levels are elevated, such
as diabetes mellitus with microangiopathy, dissemi-the rational structure-based strategies employed to de-
sign the novel CPR inhibitor are discussed. nated intravascular coagulation (DIC), and systemic lu-
pus erythromatosus, its upregulation may result in en-
hanced susceptibility to thrombosis. It has been shownResults and Discussion
that proCPR levels exceeding 129 nM correlate with a
2-fold increase in risk for deep vein thrombosis [28].Requirement of CPR Inhibitor
The mechanisms involved in the regulation of coagula- Therefore, the development of a CPR inhibitor for use
in thrombolytic therapy is highly desirable.tion and fibrinolysis (clot lysis) are complex and include
numerous protein-protein interactions. Of particular in-
terest has been the recent discovery of proCPR (58 kDa Inhibitor Design Concept
To date, no physiological inhibitor of CPR has beenglycoprotein), a metallocarboxypeptidase found in the
plasma exhibiting carboxypeptidase B-like activity fol- isolated, although metallocarboxypeptidase inhibitors
have been found in potatoes [20], tomatoes [29], round-lowing activation. Proteolytic cleavage at Arg92 yields
a 92 amino acid activation peptide (15 kDa) and a 309 worms [30], leeches [31], and some mammalian tissues
[32]. Of these, potato carboxypeptidase inhibitor (PCI;amino acid enzyme (CPR; 35 kDa). The inactive proCPR
form is present in the plasma at concentrations between Ki0.4 nM) is the most extensively studied. Additionally,
the nonspecific sulfur-containing analog of arginine,70 and 275 nM, 50-fold lower than the Km value for
activation [21]. Although proCPR can be activated by guanidinoethylmercaptosuccinic acid (GEMSA; Ki  18
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Figure 2. Potato Carboxypeptidase Inhibitor (PCI)
(A) Crystal structure of PCI from 4CPA showing the primary (cyan) and secondary (green) binding sites of PCI to CPA. In addition, the two
lysine (blue) and single arginine (red) residues we believe to be responsible for inhibiting CPR are highlighted. Disulfide bridges are shown in
yellow.
(B) Sequence of PCI showing the disulfide bond configuration (Cys8–Cys24, Cys12–Cys27, and Cys18–Cys34). The basic residues are shown
in bold and underlined. The PCI-derived peptide fragments synthesized and assayed for inhibitory activity against CPR are underlined in red.
(C) Partial crystal structure of PCI, showing the spatial arrangement of the basic residues (Lys10, Lys13, and Arg32). The C-C distances
(indicated by the dotted lines; A˚) between Lys10, Lys13, and Arg32 are shown.
(D) Sequences and molecular weight of the PCI-derived peptides (PCI-2K, PCI-R, and PCI-2K-R), our novel inhibitory peptide (CPI-2KR), and
CPI-2KR-cyclic.
M), inhibits CPR [33]. However, although GEMSA is a present, no structural data is available for CPR due to
its instability; however, the structure of PCI complexedpotent CP inhibitor, it cannot differentiate between CPR
and CPN, precluding its use for therapeutic applications. with carboxypeptidase A (CPA) is available, which
shows that PCI binds to CPA through its C terminus [38,Nonetheless, the physicochemical properties of this
small organic molecule were incorporated into the de- 39]. Although the specificity of CPA and CPR differs,
the current assumption is that PCI also binds to CPRsign of our novel CPR inhibitor.
Due to its ability to inhibit CPR but not CPN, PCI has through its C terminus. Our studies, however, have
shown that the tetrapeptide C-terminal fragment of PCIfrequently been used to assess CPR activity both in vitro
[22, 34] and in vivo [19, 35]. Supplementing t-PA doses could neither reverse the TM-induced retardation of
t-PA-induced fibrinolysis (in vitro fibrinolysis assay) norwith PCI has been shown to enhance thrombolytic ther-
apy in an animal model [19]. However, it should be noted decrease CPR activity to inhibit hippuryl-L-arginine
cleavage (data not shown). In addition, other longer N-that although PCI selectively inhibits CPR in the circula-
tion, it also inhibits CPs found in the digestive tract and C-terminal peptide fragments of PCI (Figure 2B)
also showed no inhibitory activity against CPR (data not(pancreatic CPB), brain, pituitary, pancreatic islet, and
other neuroendocrine cells (CPE/CPH), possibly causing shown), suggesting that the mechanism of inhibition is
more complex.other serious side effects upon administration [36].
Therefore, the development of a more specific CPR in- Studies on leech carboxypeptidase inhibitor (LCI)
have revealed nonspecific removal of the C-terminalhibitor of low molecular weight without toxicity is highly
desirable. Glu66 residue by both pancreatic CPA2 and CPB, which
have a restricted specificity for aromatic and positivelyPCI is a 39 amino acid protein belonging to the cystine
knot family [37]. Due to the presence of three disulfide charged C-terminal residues, respectively. Although the
removal mechanism remains a mystery, no decrease inbonds (Figure 2A), it has a compact structure, compris-
ing a globular core (Cys8–Cys34) and flexible N and inhibitory activity was observed [31]. Similarly, X-ray
crystallographic analysis of PCI complexed to CPA re-C termini (Glu1–Ile7 and Glu35–Lys39, respectively). At
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Figure 3. Competitive Inhibition of PCI and PCI-2K-R against CPR
(A) Lineweaver-Burke plot plot (1/v versus 1/[S]) for PCI (closed triangle) and PCI-2K-R (open triangle) showing competitive inhibition relative
to no inhibitor (closed diamond).
(B) Kinetic constants (Vmax, Km, kcat, and Ki) for CPR alone and in the presence of PCI and PCI-2K-R. The R2 values for the linear regressions
are included.
(C) CPR binding to PCI-derived 10-mer peptides on a cellulose membrane. The thick bold line indicated the peptides that bound CPR. Basic
residues are shown in bold.
vealed that the C-terminal Gly39 residue was also re- for the observed inhibitory activity. The first peptide
(PCI-2K) contained the two lysine residues and the sec-moved [38, 39]. Likewise, the removal mechanism of the
nonspecific C-terminal Gly39 residue of PCI by CPA ond peptide (PCI-R) contained the arginine residue (Fig-
ure 2D). These peptides represent two regions of PCIis unclear, however, it has been proposed to facilitate
coordination of the newly generated C-terminal Val38 maintained in close spatial proximity by three disulfide
bridges. As a starting point, under high dilution condi-residue of PCI to the catalytic active site of CPA [31].
In contrast to these studies, our results suggest that tions, equimolar amounts of peptides PCI-2K and PCI-R,
both containing a single cysteine residue, were oxidizedthe C terminus of PCI may not be responsible for its
inhibitory activity against CPR. Since the function of to form the heterodimer PCI-2K-R. In contrast to the
monomeric peptides, for which no activity was observedCPR is to remove C-terminal Lys and Arg residues from
fibrin clots and inflammatory mediators, respectively, (data not shown), the heterodimer, PCI-2K-R, was found
to be a weak competitive inhibitor of CPR (Figure 3A).we investigated the possibility that PCI inhibits CPR by
competitively binding via these residues of PCI. Close Furthermore, kinetics studies revealed that compared
to PCI (Km 12.3 M; Ki 1.4 nM; Figure 3B), the inhibitoryinspection of the X-ray structure of PCI complexed to
CPA [38, 39] revealed that the two Lys residues and a activity of PCI-2K-R was 290-fold lower (Km 4.2 M; Ki
407.1 nM; Figure 3B). The reduced inhibitory activitysingle Arg residue of the former are orientated in the
same direction (Figure 2A). Furthermore, although these of this PCI-derived peptide may be attributed to the
absence of two of the three disulfide bridges found inresidues are far from each other in the linear sequence
of PCI, the disulfide bonding configuration brings them wild-type PCI, effectively resulting in increased mobility
of all residues. To support these results, the interactionin close proximity to one another (Figure 2C), directly
opposite the primary (residues 37–39) and secondary between CPR and 10-mer PCI peptide fragments syn-
(residues 15, 23, 28, 29, and 30) binding domains of PCI thesized on a cellulose membrane was also examined.
for CPA (Figure 2A). The possible involvement of these The results, shown in Figure 3C, indicated that CPR
basic residues for the inhibition of CPR was subse- bound with peptides containing two Lys residues and
quently examined. also with peptides containing an Arg residue at their N
terminus. Inaccessible Lys and Arg residues, located
proximal to the membrane, did not interact appreciablyHeterodimeric Peptide
We designed and synthesized two peptide fragments with CPR. It should be noted that while the cellulose
binding experiments provide relevant information onwhich mimicked the PCI regions possibly responsible
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Figure 4. Competitive Inhibition of CPI-2KR against CPR
(A) In vitro TM-induced retardation (gray squares) of t-PA-induced fibrinolysis (gray triangles) due to the conversion of proCPR to CPR by the
T/TM complex. Inhibition of CPR by PCI (12 M) is indicated by reversal of the TM-induced retardation of t-PA-induced fibrinolysis (black
diamonds).
(B) Dose-dependent inhibition by CPI-2KR at various concentrations (8, 16, 32, 63, 126, and 253 M) on the TM-induced retardation of t-PA-
induced fibrinolysis.
(C) Lineweaver-Burke plot (1/v versus 1/[S]) for CPI-2KR at various concentrations (63, 126, and 253 nM) relative to no inhibitor (0 M).
(D) Dixon Plot (1/v versus [I]) for CPI-2KR for increasing substrate concentrations (1.2–6.0 mM; indicated by arrow). Replotting of slopes of
Dixon plot versus 1/[S] showing competitive inhibition (inset).
(E) Kinetic constants (Vmax, Km, kcat, and Ki) for CPR alone and in the presence of CPI-2KR. The R2 values for the linear regressions are included.
possible PCI binding domains, they do not provide cor- 2K-R could not reverse the TM-induced retardation of
t-PA-induced fibrinolysis (data not shown). The competi-responding information on the actual biological activity.
Furthermore, the observed interaction may be influ- tive inhibition of PCI-2K-R might not be strong enough
to support t-PA function.enced/enhanced by polyvalency effects.
In human plasma, t-PA-induced fibrinolysis is sup-
pressed by the addition of TM (10 nM). This suppres- Novel Linear Peptide Inhibitor
In view of the promising results obtained for the peptidesion could be due to the conversion of proCPR to its
active CPR form, which is inhibited by the presence PCI-2K-R, the crystal structure of PCI was more closely
examined. In particular, the spatial C-C distances be-of PCI (12 nM), thus permitting fibrinolysis to proceed
(Figure 4A). However, the heterodimeric peptide PCI- tween the Lys and Arg residues were measured (Figure
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Figure 5. CD Spectra of CPR, CPI-2KR, and the CPR/CPI-2KR Complex
(A) CD spectra of CPR (dark blue), CPI-2KR (pink), and the CPR/CPI-2KR complex immediately after mixing (Complex0; light blue) and 30 min
after mixing (Complex30; gold). Spectra were recorded at 4C in Tris-HCl (50 mM, pH 7.5).
(B) Secondary structure estimations determined for the CD spectra shown in (A).
2C). Subsequently, a novel linear peptide (CPI-2KR, the inhibitory mechanism of CPI-2KR (Figure 4D). Re-
plotting of the slopes of the Dixon plot against 1/[S]CKPAKNARC; Figure 2D) was designed based on the
data obtained from PCI. The peptide included the two confirmed that CPR-2KR is a competitive inhibitor of
CPR, given that the line went through the origin (FigureLys and one Arg residues from PCI (Lys10, Lys13, and
Lys32) expected to be responsible for the interaction 4D, inset). The Km, Kmapp , and Vmax were determined from
observed between PCI and CPR. The spatial separation the data obtained for no inhibitor and the highest inhibi-
of these basic residues was approximated to resemble tor concentration (253 nM) from the Lineweaver-Burke
that of PCI. In addition, the proline (Pro11) residue adja- plots (Figure 4E). These values were in turn used to
cent to the Lys10 residue and the alanine (Ala31) residue calculate the dissociation constant of CPI-2KR (Ki). CPI-
adjacent to the Arg32 residue of PCI were included. At 2KR was found to have a relatively low Ki (8.8 nM; 6-fold
the N and C termini, cysteine (Cys) residues were added higher than that of PCI), indicating that it binds to CPR
so as to permit cyclization of the peptide and reduce with a relatively strong affinity. Of particular interest is
conformational flexibility (CPI-2KR-cyclic; Figure 2C). the significant improvement in binding affinity for CPR
The Cys residue between the two Lys residues (Lys10 (46-fold stronger than PCI-2K-R), with the observed
and Lys13; Figure 2C) was replaced by an Ala residue concomitant increase in inhibitory activity, when com-
to remove any possible interference with cyclization. pared to PCI-2K-R. This may be attributed to the close
Peptide CPI-2KR was assayed for its ability to reverse spatial proximity of the K and R residues in the absence
the TM-induced retardation of t-PA-induced fibrinolysis. of disulfide bridges, as for PCI.
Remarkably, this short linear peptide showed dose-
responsive inhibition of TM-induced retardation of t-PA- Structure Studies
induced fibrinolysis (Figure 4B), although the effective Using similar conditions to those of the enzyme kinetics
inhibitory concentration of CPI-2KR (126 nM) was 10- studies, circular dichroism (CD) spectroscopy was em-
fold lower that of PCI (12 nM). In contrast, cyclization ployed to analyze the solution conformation of CPR
of the peptide (CPI-2KR-cyclic) resulted in a dramatic alone and when complexed with CPI-2KR. Due to the
loss of inhibitory activity (data not shown), indicating instability of CPR, the studies were performed at 4C.
that a certain degree of structural mobility may be nec- After mixing CPI-2KR (150 M) with CPR (1.1 M), a
essary for the peptide to adopt the correct conformation significant change in the CD spectrum was observed
for binding to CPR. Furthermore, mutation studies indi- (Figure 5A). The peptide is predominantly in a random
cated that the basic and Cys residues of CPI-2KR are conformation, and CPR predominantly displays -heli-
essential for inhibitory activity. In particular, replace- cal and  sheet structure (Figure 5B). The CD spectra
ment of the basic residues by alanine residues, removal of the CPR/CPI-2KR complex immediately after mixing
of the N- and C-terminal Cys residues, or replacement (Complex0) shows a significantly less random structure,
of these residues by either Ala or methionine (Met) re- particularly after 30 min incubation at 4C (Complex30),
sulted in a loss of biological activity (data not shown). suggesting that the conformation of CPR was altered
when the CPR/CPI-2KR complex was formed. PCI,
Mechanism of Inhibition which predominantly contains  sheet structure, was
In order to gain insight into the inhibitory mechanism also complexed with CPR as a control. Similarly, a con-
of CPI-2KR against CPR, a classical Henri-Michaelis- formational change was observed when the CPR/PCI
Menten kinetics analysis was performed. Since the Line- was formed. In particular, a slight increase in -helical
weaver-Burke plot (Figure 4C) is prone to error, particu- structure was observed with a concomitant increase in
larly at low concentrations of inhibitor and substrate, random structure and decrease in  sheet structure
(data not shown).the Dixon plot (1/v versus [I]) was employed to evaluate
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Figure 6. NMR and Molecular Modeling
Studies
(A) C-C distance (A˚) between the basic resi-
dues of PCI-2K-R, CPI-2KR, CPI-2KR-cyclic,
and PCI.
(B) Energy minimized structure of CPI-2KR
showing the C-C distance (A˚) between the
basic residues.
(C) Energy minimized structure of CPI-2KR-
cyclic showing the C-C distance (A˚) be-
tween the basic residues.
(D) NMR structure of CPI-2KR-cyclic showing
the C-C distance (A˚) between the basic res-
idues.
(E) NMR structure of CPI-2KR-cyclic (Arg in
red, Lys in blue, Cys in yellow, and Pro in
green) superimposed on energy minimized
structure (Arg in pink, Lys in cyan, Cys in
orange, and Pro in mint).
Nuclear magnetic resonance (NMR) and molecular ergy conformation, following high-temperature simu-
lated annealing energy minimization, is shown in Figuremodeling (MM) studies provided insight into the possible
conformation of the cyclic and linear peptides. Prelimi- 6B. Although the Arg8–Lys2 C-C distance is almost
half that of PCI, this peptide is flexible enough, due tonary MM studies revealed that CPI-2KR can adopt a
conformation with Lys and Arg residue C-C distances the lack of a disulfide bridge between the terminal Cys
residues, to adopt a more suitable conformation to bindcomparable to those of PCI (Figure 6A). The lowest en-
Figure 7. Inhibition of CPN by GEMSA But Not by CPI-2KR
(A) Lineweaver-Burke plot (1/v versus 1/[S]) for GEMSA (closed square and closed triangle; 425 and 2126 nM, respectively) and CPI-2KR
(open diamonds; 506 nM) relative to no inhibitor (closed diamond).
(B) Kinetic constants (Vmax, Km, and kcat) for CPN alone and in the presence of GEMSA and CPI-2KR. The R2 values for the linear regressions
are included.
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Peptides were then cleaved from the resin, with concomitant re-to CPR. For comparison, the cyclic peptide (CPI-2KR-
moval of sidechain protecting groups by treatment with trifluoroace-cyclic) was also subjected to this procedure (Figure 6C);
tic acid (TFA; 80%), thioanisol (12%), 1,2-ethanedithol (EDT; 6%),however, due to steric hindrance, the C-C distances and m-cresol (2%). After cleavage, the peptides were precipitated
of Lys and Arg were significantly different from those with 2 volumes of cold ether for 10 min, collected by centrifugation,
of PCI (Figure 6A). Although NMR spectroscopy could washed two times with cold ether, and left to dry overnight. Purifica-
tion was carried out by reversed-phase HPLC (Waters 741 Datanot provide any structural information for the linear pep-
Module, Waters 484 Tunable Absorbance Detector; Waters 600Etide due to the large conformational flexibility of the
System Controller). Samples of crude peptide were chromato-molecule, the cyclic peptide structure was deduced
graphed on a Waters Delta-Pak C18 column (40 	 100 mm, 15 m,(Figure 6D). From this data, we can see that the spatial
100 A˚ particles) with linear gradient: Milli-Q water/acetonitrile in
separation of the Lys and Arg residues, for both the 0.1% TFA. Peptide mass was confirmed using matrix-assisted laser
model and NMR structures of CPI-2KR-cyclic, signifi- desorption time-of-flight (MALDI-TOF) mass spectrometry (Kom-
pact Maldi II, Kratos Analytical, Shimadzu, Japan). Lyophilized pep-cantly differs from that of PCI. Furthermore, the C-C
tides were stored desiccated at 30C.distances of Lys and Arg of the NMR structure of CPI-
2KR-cyclic significantly differed from those of model
Formation of Heterodimeric Peptidestructure obtained using the high-temperature simu-
The heterodimer, PCI-2K-R, was formed by mixing equimolar
lated annealing protocol. However, despite this, our amounts (1 mM in Milli-Q water/0.5% acetic acid) of PCI-2K and
studies showed that a cyclic 9-mer peptide cannot have PCI-R in 500 ml of Milli-Q water (pH 8.2). After mixing for at least 1
all basic residue side chains facing in the same direction day, the pH was readjusted to 2.2 and the solution was filtered
through a 0.45 micron filter and desalted using isocratic conditions(Figure 6E). In both cases, one of the Lys residues is
(50% acetonitrile) on a Waters Delta-Pak C18 column. The hetero-in the down position, while the other Lys and the Arg
dimeric peptide (CPI-2KR) was separated from the monomeric (PCI-residues are in the up position. Therefore, CPI-2KR-
2K and PCI-R) and homodimeric species using linear gradient condi-
cyclic might be unable to adopt a suitable conformation tions identical to those outlined in the Peptide Synthesis section
for binding to CPR due to steric hindrance. (above).
The formation of disulfide bonds was indirectly determined by
monitoring the absence of SH groups. Ellman’s reagent (DTNB; 5,5
-No Effect on Carboxpeptidase N
Dithio-bis(2-nitrobenzoic acid); 0.1 mM [41]) in potassium dihydro-Finally, as shown in Figure 7, CPI-2KR did not exhibit
gen phosphate (1.2 mM), disodium hydrogen phosphate buffer (95any inhibitory activity against CPN even at 506 nM, 2-fold
mM) forms a mixed disulfide with thiols, liberating the chromophore
higher than the concentration required for CPR inhibition 5-mercapto-2-nitrobenzoic acid (absorption maximum 410 nm, 
(Figure 7). In contrast, GEMSA, which inhibits CPR at 13, 600 cm1M1). Peptide solutions (0.25 M) were mixed with
increasing concentrations of Ellman’s reagent (0, 0.03, 0.06, 0.07518 M [40], inhibited CPN at a lower concentration of
M) and read at 412 nm.425 nM.
Cellulose-Bound Peptide SynthesisSignificance
Cellulose-bound overlapping peptides (10-mers) derived from PCI
were prepared using an Auto-Spot Robot ASP 222 peptide synthe-
CPI-2KR was designed using a rational structure-based siser (ABiMED, Langenfeld, Germany; Software DIGEN, Jerini Bio-
Tools GmbH, Berlin, Germany) on Whatman 50 (Whatman, Maid-strategy which combined information obtained from
stone, United Kingdom) membranes [42]. Anchor groups werethe crystal structure of a known CPR inhibitor, namely
obtained by homogeneous derivatisation of the hydroxyl groupsPCI, and the biological known function of the enzyme.
with Fmoc--alanine. Following deprotection using 20% pipiredineTaken together, the information yielded a successful
in DMF, Fmoc amino acids (0.5 M), activated using HOBT and N,
peptide candidate, which effectively lowered the TM- N
-diisopropylcarbodiimide (DIPCI), were applied and allowed to
induced retardation of t-PA-induced fibrinolysis similar react for 20 min. After 10 cycles, the sidechain protecting groups
were removed using trifluoroacetic acid (TFA; 80%), thioanisolto PCI, acting through a competitive inhibitory mecha-
(12%), 1,2-ethanedithol (EDT; 6%), and m-cresol (2%).nism, specifically inhibiting CPR without affecting CPN.
Membranes were washed four times with phosphate bufferedThis small novel CPR inhibitor is thus a useful agent for
saline/0.05% Tween20 (pH 7.3; PBS-T) and blocked with PBS-T-use in the prevention and/or treatment of thrombosis,
1% BSA overnight at 4C. CPR (10 g/ml in blocking solution) or
while representing a lead molecule for the design of PBS-T-1% BSA (control) were allowed to interact with the bound
smaller organic molecules for use as adjuncts to peptides at 4C overnight. The following day, membranes were incu-
bated with an FITC-conjugated anti-proCPR monoclonal antibody,thrombolytic therapy.
10G1 (10G1-FITC; 10g/ml), which also recognizes CPR [43], subse-
quent to being washed four times with PBS-T, twice with PBS-Experimental Procedures
T-1M NaCl, and twice with PBS-T. After 4 hr incubation at room
temperature, the membranes were read on a fluorescence laserPeptide Synthesis
scanner (FLA3000; Fujifilm, Japan) and analyzed using the ArrayPeptides were synthesized using an AMS 422 Multiple Peptide Syn-
Gauge software (version 1.0; Fujifilm, Japan).thesiser (ABiMED, Langenfeld, Germany) using standard solid-
phase synthesis techniques and 9-fluorenylmethoxycarbonyl
(Fmoc) amino acids (Watanabe Chemical Industries Ltd., Hiroshima, Purification of proCPR and CPN
ProCPR was purified to homogeneity as previously described [3].Japan). In situ activation was by 2-(1H-Benzotriazole-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HBTU) with N-methyl- The pure enzyme showed a single band by SDS-polyacrylamide
gel electrophoresis (SDS-PAGE) at 60 kDa and was converted bymorpholine (NMM) and hydroxybenzotriazole (HOBT) as catalytic
bases. Amidated peptides (25 mole scale) were prepared using thrombin/thrombomodulin to the activated form resulting in a band
at approximately 35 kDa in SDS-PAGE analysis. CPN was purifiedFmoc-PAL-PEG-PS resin (PerSeptive Biosystems; Warrington, UK).
All residues were double coupled in N,N-dimethylformamide (DMF; to homogeneity as previously described [8]. The enzyme gave three
bands on SDS-PAGE at 83 kDa, 53 kDa, and 50 kDa, correspondingPeptide synthesizer grade; Watanabe Chem. Ind. Ltd.) N-methylpyr-
rolidone (NMP) and dichloromethane (DCM). Deprotection was to the two large identical glycosylated subunits and the two smaller
active subunits, respectively.achieved using 20% pipiredine in DMF.
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Hippuryl-L-Arginine Hydrolysis Assay petitive inhibitor, the slope replot goes through the origin, while that
for a mixed-type inhibitor does not.Carboxypeptidase activity for CPR and CPN samples used for the
enzyme kinetics and fibrinolysis assay experiments was determined
by use of hippuryl-L-arginine (Peptide Institute Inc., Osaka, Japan) Enzyme Kinetics for CPN
as described previously [44]. Briefly, 30 mM hippuryl-L-arginine in The effect of CPI-2KR on purified CPN was determined using hip-
50 mM HEPES (pH 8.2) was incubated with test samples at 37C puryl-L-arginine as the substrate. Guanidinoethylmercaptosuccinic
for 45 min, and released hippuric acid was quantitated by HPLC acid (GEMSA) was used as a positive control. CPI-2KR (500 g/ml),
following extraction with ethyl acetate. GEMSA (100, 500 g/ml), or Tris-HCl buffer (50 mM; pH 7.5) was
added to CPN (10 g/ml) at a 1:7 ratio. Identical conditions to those
used for the CPR kinetics experiments were subsequently applied.Enzyme Kinetics for CPR
The activity of the CPR inhibitors was determined against hippuryl-
In Vitro Fibrinolysis AssayL-arginine cleavage by purified CPR. The peptides PCI-2K-R, CPI-
Human plasma was obtained by centrifugation of citrated blood at2KR, PCI (500, 250/125/62.5, 50 g/ml, respectively) or Tris-HCl
3000 	 g for 15 min at room temperature. In a 96-well microtiterbuffer (50 mM; pH 7.5) were added to active CPR (40–320 g/ml)
plate, 20 l of a thrombin/calcium mix (50 l calcium [CaCl2; 1 M],at a 1:7 ratio. After thorough mixing, 20l was incubated with various
20 l of thrombin [T; 500 U/ml], and 430 l of Tris buffer [50 mM,concentrations of hippuryl-L-arginine (1.2–6.0 mM), for 15 min at
pH 7.5]) was added, followed by 10 l of thrombomodulin (TM; final37C [21]. Contrary to the reported procedure (HCl addition, followed
concentration 8 nM). Subsequently, 10 l of peptide solution in Trisby NaOH neutralization), the reaction was stopped with the addition
buffer (16 g/ml–500 g/ml), Tris buffer, or PCI (50 g/ml) wasof sodium phosphate buffer (100 l; 0.25 M), immediately followed
added. After the addition of 50 l of a t-PA/plasma mix (8 l of t-PAby 3% cyanuric chloride in 1,4-dioxane (75 l). After mixing well,
[130 g/ml] mixed with 1 ml of prewarmed citrated plasma [37Cthe generation of hippuric acid was determined by measuring the
for 5 min]), the plate was immediately read at 420 nm every 5 min forOD at 405 nm on a SpectraMAX 250 Microplate Spectrophotometer
2 hr on a SpectraMAX 250 Microplate Spectrophotometer (Molecular(Molecular Device Corporation, Sunnyvale, CA, USA). Hippuric acid
Device Corporation, Sunnyvale, CA, USA). Lysis time was defined(0–2.0 mM) in Tris buffer was used as the standard.
as the time required for the absorbance to reach half the differenceA kinetics analysis of the CPR-catalysed hydrolysis of hippuryl-
between the plateau reached after clotting and baseline achievedL-arginine in the absence and presence of inhibitory molecules was
at clot lysis.performed. The Lineweaver-Burk reciprocal plot, based on re-
arrangement of the Henri-Michaelis-Menten equation into a linear
Nuclear Magnetic Resonance Studiesform, was applied:
Samples were prepared by dissolving CPI-2KR or CPI-2KR-cyclic
in 500 l of water containing 10% D2O. The final peptide concentra-1
v

Km
Vmax
1
[S]

1
Vmax tion of the solution was 3 mM. The pH of the sample solution was
adjusted to 5.0. NMR experiments were carried out at 5C on a
where v (in mM·s1) is the instantaneous or initial velocity, [S] (mM) Bruker DMX-500 spectrometer. Two-dimensional NMR experiments
is the substrate concentration, Km (mM) is equivalent to the substrate including HOHAHA [45] and ROESY [46] were carried out using the
concentration that yields half-maximal velocity, and Vmax (mM·s1) is WATERGATE scheme for water suppression [47], while in the case
the maximum velocity. For competitive inhibition, where the inhibitor of DQF-COSY [48], a low-power irradiation of the water frequency
competes with the substrate for binding to the enzyme, the following was used during the relaxation delay. HOHAHA spectra were re-
mechanism was assumed: corded with mixing time of 60 ms. ROESY spectra were recorded
with mixing times of 200 ms, 300 ms, and 400 ms. Processing and
analyses of the spectra were done using the Bruker XWINNMR.E  S ⇀↽
k
1
k1
ES →
k
2
P
Interproton distance constraints were obtained from the ROESY
spectra observed with mixing times of 300 ms. Observed ROE data
were classified into four distance ranges, 1.8–2.7 A˚, 1.8–3.5 A˚,
1.8–5.0 A˚, and 3.0–6.0 A˚, corresponding to strong, medium, weak,
I where Ki 
[E][I]
[EI] and very weak ROE values, respectively. The upper boundary of
ROEs involving amide protons was extended to 2.9 A˚ for strong
Ki ↑↓ ROEs and to 3.5 A˚ for medium ROEs to account for the higher
observed intensity of this type of intensity [49]. In addition, a 0.5 A˚EI
correction [49] was added to the upper boundary of the distances
involving methyl protons. Structure calculations were performed onIn competitive inhibition, the apparent Vmax is not affected by increas-
41 interproton distance constraints derived from the 2D ROESYing inhibitor concentrations because once substrate binds, the reac-
spectrum, 7 dihedral angle constraints derived from 1H 1D-NMRtion proceeds normally (i.e., Vmax depends only on maximum ES
spectrum, and one disulfide bond restraint. All calculations werecomplex concentration, which only depends on the total amount of
carried out using dynamic simulated annealing protocols in the pro-enzyme present). However, the apparent Km increases (i.e. a higher
gram DYNAMO. The structure was analyzed using the program PRO-substrate concentration is required for a given velocity) by a factor
CHECK [50].of [1 ([I]/Ki)]. Therefore, the dissociation constant for a competitive
inhibitor, Ki, can be calculated from:
Molecular Modeling Studies
A conformational search for the global energy minimum of the mole-
Kmapp  Km 1  [I]Ki cules (PCI-2K-R, CPI-2KR, and CPI-2KR-cyclic) was performed in
vacuo using a molecular dynamics (MD) simulated annealing strat-
where Kmapp is the apparent Km for a given inhibitor concentration. egy. The consistent-valence forcefield (CVFF) was used for the po-
tential energy calculations, which included all bond, torsion, out-of-The Dixon plot (1/v versus [I] in the presence of different concen-
plane, and nonbond van der Waals and electrostatic terms. A cutofftrations of substrate) provides a more diagnostic way of identifying
distance of 13 A˚ was used for the calculation of the nonbond interac-the type of inhibition and determining the Ki:
tion energy (van der Waals and electrostatic terms) and a dielectric
constant of 1 was used for the calculation of the electrostatic energy.1


Km
VmaxKi[S]
[ı] 
1
Vmax
1  Km[S] Initially, to relax the peptides from strain, a steepest descent minimi-
zation was applied for 5,000 iterations, until a maximum derivative of
less than 1.00 kcal/A˚ was achieved. This was followed by conjugateSince a linear mixed-type inhibitor yields the same type of Dixon
plot as a competitive inhibitor, the slopes of the Dixon plots versus gradient minimization for 10,000 iterations, until a maximum deriva-
tive of 0.01 kcal/A˚ was achieved. The system was subsequently1/[S] can be replotted to distinguish one from the other. For a com-
Chemistry & Biology
1138
equilibrated at 200 K for 10 ps and then rapidly heated to 900 K by 7. Campbell, W., Okada, N., and Okada, H. (2001). Carboxypepti-
dase R is an inactivator of complement-derived inflammatoryincreasing the temperature by 100 K every 1 ps. The configuration
space was sampled at 900 K for 10 ps. After the high temperature peptides and an inhibitor of fibrinolysis. Immunol. Rev. 180,
162–167.dynamics, the system was cooled slowly by decreasing the temper-
ature by 25 K every 1 ps, until the temperature reached 200 K. At 8. Plummer, T.H., Jr., and Hurwitz, M.Y. (1978). Human plasma
carboxypeptidase N. Isolation and characterization. J. Biol.this stage the system was reequilibrated for a further 10 ps and the
configuration space was sampled once again for 30 ps. The lowest Chem. 253, 3907–3912.
9. Plummer, T.H., Jr., and Ryan, T.J. (1981). A potent mercaptoenergy conformation of each peptide from the MD simulation was
selected for analysis. The C-C distances between the basic resi- bi-product analogue inhibitor for human carboxypeptidase N.
Biochem. Biophys. Res. Commun. 98, 448–454.dues of each peptide were measured using InsightII (MSI, San
Diego). 10. Tan, F., Jackman, H., Skidgel, R.A., Zsigmond, E.K., and Erdos,
E.G. (1989). Protamine inhibits plasma carboxypeptidase N, the
inactivator of anaphylatoxins and kinins. Anesthesiology 70,Circular Dichroism Spectropolarimetry
267–275.Circular dichroism spectra were measured over the range 190–250
11. Skidgel, R.A., Deddish, P.A., and Davis, R.M. (1988). Isolationnm, using a Jasco-715 spectropolarimeter (Jasco, Tokyo, Japan)
and characterization of a basic carboxypeptidase from humancoupled to an Eyela Cooling Thermo Pump CTP-200 (Tokyo Rikaki-
seminal plasma. Arch. Biochem. Biophys. 267, 660–667.kai Co. Ltd, Tokyo, Japan). Spectra were obtained in Tris-HCl (50
12. Shinohara, T., Sakurada, C., Suzuki, T., Takeuchi, O., Campbell,mM, pH 7.5) at 4C using a cell with a path length of 0.1 cm. CPR
W., Ikeda, S., Okada, N., and Okada, H. (1994). Pro-carboxypep-(40 g/ml) and CPI-2KR (160 g/ml) concentrations were similar to
tidase R cleaves bradykinin following activation. Int. Arch. Al-those used for the kinetics studies. Data points were recorded at a
lergy Immunol. 103, 400–404.scan speed of 50 nm/min, bandwidth of 1.0 nm, 8 s response, and
13. Campbell, W., Lazoura, E., Okada, N., and Okada, H. (2002).0.1 nm resolution. Four repeat scans were used to obtain the final
Inactivation of C3a and C5a octapeptides by carboxypeptidaseaveraged spectra. Following baseline correction, the observed
R and carboxypeptidase N. Microbiol. Immunol. 46, 131–134.ellipticity, , was converted to mean residue ellipticity [] (deg cm2
14. Redlitz, A., Tan, A.K., Eaton, D.L., and Plow, E.F. (1995). Plasmadmole1), using the relationship:
carboxypeptidases as regulators of the plasminogen system.
J. Clin. Invest. 96, 2534–2538.
[] 

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where l is the path length in centimeters, c is the molar concentra- 43–46.
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